Chronic liver disease(CLD)is prevalent in the United States and globally.It is a major source of mortality and morbidity with loss of productivity due to disability(1).Recent advances in the treatment of hepatitis C v...Chronic liver disease(CLD)is prevalent in the United States and globally.It is a major source of mortality and morbidity with loss of productivity due to disability(1).Recent advances in the treatment of hepatitis C virus(HCV)infection has led to some reduction in cirrhosis development from this etiology,however,increasing rates of alcohol use and metabolic dysfunction associated liver disease(MASLD)threaten to counter this progress(1).The progression of CLD to cirrhosis and its subsequent squeal-complications of portal hypertension such as esophageal varices,hepatic encephalopathy,and hepatocellular carcinoma(HCC)-accounts for much of the mortality and morbidity in patients with cirrhosis(2).For all these reasons,assessing patients with CLD for significant fibrosis is essential for early intervention to slow progression and reduce the incidence of these serious complications.展开更多
Pancreatic ductal adenocarcinoma(PDAC)accounts for over 90%of pancreatic cancers and is the seventh leading cause of cancer deaths worldwide(1).Considered one of the most aggressive cancers,PDAC is associated with non...Pancreatic ductal adenocarcinoma(PDAC)accounts for over 90%of pancreatic cancers and is the seventh leading cause of cancer deaths worldwide(1).Considered one of the most aggressive cancers,PDAC is associated with nonspecific symptoms and often presents with widespread metastasis at the time of diagnosis,with an average 5-year survival rate of less than 10%(2).It has both genetic and environmental risk factors and can arise from several precursor lesions,primarily pancreatic intraepithelial neoplasia(PanIN)and,to a lesser extent,intraductal papillary mucinous neoplasms(IPMNs)and mucinous cystic neoplasms.As the predominant form of pancreatic cancer,PDAC poses challenges due to its complex pathology,and understanding of its pathogenesis is critical for management.展开更多
文摘Chronic liver disease(CLD)is prevalent in the United States and globally.It is a major source of mortality and morbidity with loss of productivity due to disability(1).Recent advances in the treatment of hepatitis C virus(HCV)infection has led to some reduction in cirrhosis development from this etiology,however,increasing rates of alcohol use and metabolic dysfunction associated liver disease(MASLD)threaten to counter this progress(1).The progression of CLD to cirrhosis and its subsequent squeal-complications of portal hypertension such as esophageal varices,hepatic encephalopathy,and hepatocellular carcinoma(HCC)-accounts for much of the mortality and morbidity in patients with cirrhosis(2).For all these reasons,assessing patients with CLD for significant fibrosis is essential for early intervention to slow progression and reduce the incidence of these serious complications.
文摘Pancreatic ductal adenocarcinoma(PDAC)accounts for over 90%of pancreatic cancers and is the seventh leading cause of cancer deaths worldwide(1).Considered one of the most aggressive cancers,PDAC is associated with nonspecific symptoms and often presents with widespread metastasis at the time of diagnosis,with an average 5-year survival rate of less than 10%(2).It has both genetic and environmental risk factors and can arise from several precursor lesions,primarily pancreatic intraepithelial neoplasia(PanIN)and,to a lesser extent,intraductal papillary mucinous neoplasms(IPMNs)and mucinous cystic neoplasms.As the predominant form of pancreatic cancer,PDAC poses challenges due to its complex pathology,and understanding of its pathogenesis is critical for management.
